NCT05680922View on ClinicalTrials.gov

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

January 31, 2028

Study Completion Date

March 31, 2028

Conditions
Small Cell Lung Cancer Extensive StageLarge Cell Neuroendocrine Carcinoma of the Lung
Interventions
BIOLOGICAL

LB2102

DLL3 directed autologous Chimeric Antigen Receptor T-cells

Trial Locations (4)

10017

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

33612

RECRUITING

Moffitt Cancer Center, Tampa

40536

RECRUITING

University of Kentucky - Markey Cancer Center, Lexington

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Legend Biotech USA Inc

INDUSTRY